Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients

Journal of Clinical Oncology

Volumn 21, Issue 11, 2003, Pages 2147-2155

  Tremblay, Pierre Benoit ^a   Kaiser, Rolf ^a   Sezer, Orhan ^a   Rösler, Nadja ^a   Schelenz, Claudia ^a   Possinger, Kurt ^a   Roots, Ivar ^a   Brockmöller, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ANTIEMETIC AGENT; SEROTONIN 3 RECEPTOR; THREONINE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; ONDANSETRON; SEROTONIN RECEPTOR; TROPISETRON;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA FLANKING REGION; DNA POLYMORPHISM; DRUG EFFICACY; EXON; GENE DELETION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STANDARDIZATION; VISUAL ANALOG SCALE; ADOLESCENT; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETICS; GERMANY; MALE; MIDDLE AGED; NEOPLASM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STATISTICAL MODEL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; GENE DELETION; GERMANY; HUMANS; INDOLES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; ONDANSETRON; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, SEROTONIN; STATISTICS, NONPARAMETRIC; VOMITING;

EID: 0037868158     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.164     Document Type: Article

References (25)

1. Stewart DJ: Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 68:304-313, 1990
2. Andrews PL, Davis CJ: The mechanism of emesis induced by anticancer therapies, in Andrews PL SG (ed): Emesis in Anti-Cancer Therapy. London, England, Chapman and Hall, 1993, pp 113-161
3. Tyers MB, Freeman AJ: Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 49:263-268, 1992
4. Miller AD, Leslie RA: The area postrema and vomiting. Front Neuroendocrinol 15:301-320, 1994
5. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: A comparison of their pharmacology and clinical efficacy. Drugs 55:173-189, 1998
6. Cunningham D, Hawthorn J, Pople A, et al: Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1:1461-1463, 1987
7. Jantunen IT, Kataja VV, Muhonen TT: An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66-74, 1997
8. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines-American Society of Clinical Oncology. J Clin Oncol 17:2971-2994, 1999
9. Kaiser R, Sezer O, Papies A, et al: Patient-tailored antiemetic treatment with 5-HT3 receptor antagonists according to CYP2D6 genotypes. J Clin Oncol 20:2805-2811, 2002
10. Maricq AV, Peterson AS, Brake AJ, et al: Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254:432-437, 1991
11. Jackson MB, Yakel JL: The 5-HT3 receptor channel. Annu Rev Physiol 57:447-468, 1995
12. Miyake A, Mochizuki S, Takemoto Y, et al: Molecular cloning of human 5-hydroxytryptamine 3 receptor: Heterogeneity in distribution and function among species. Mol Pharmacol 48:407-416, 1995
13. Belelli D, Balcarek JM, Hope AG, et al: Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol Pharmacol 48:1054-1062, 1995
14. Davies PA, Pistis M, Hanna MC, et al: The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397:359-363, 1999
15. Dubin AE, Huvar R, D'Andrea MR, et al: The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem 274:30799-30810, 1999
16. Bruss M, Göthert M, Hayer M, et al: Molecular cloning of alternatively spliced human 5-HT3 receptor cDNAs. Ann N Y Acad Sci 861:234-235, 1998
17. Boess FG, Martin IL: Molecular biology of 5-HT receptors. Neuropharmacology 33:275-317, 1994
18. Boess FG, Beroukhim R, Martin IL: Ultrastructure of the 5-hydroxytryptamine 3 receptor. J Neurochem 64:1401-1405, 1995
19. Bruss M, Barann M, Hayer-Zillgen M, et al: Modified 5-HT3A receptor function by co-expression of alternatively spliced human 5-HT3A receptor isoforms. Naunyn Schmiedebergs Arch Pharmacol 362:392-401, 2000
20. Fletcher S, Barnes NM: Desperately seeking subunits: Are native 5-HT3 receptors really homomeric complexes? Trends Pharmacol Sci 19:212-215, 1998
21. Hesketh PJ, Kris MG, Grunberg SM, et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997
22. Hesketh PJ: Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice. Oncologist 4:191-196, 1999
23. Italian Group for Antiemetic Research: Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis: Italian Group for Antiemetic Research. J Clin Oncol 16:2937-2942, 1998
24. Sachse C, Brockmöller J, Bauer S, et al: Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295, 1997
25. Brown GW, Paes D, Bryson J, et al: The effectiveness of a single intravenous dose of ondansetron. Oncology 49:273-278, 1992